Professor, Department of Hematology & Oncology, Samsung Medical Center

Speciality Interests

Medical Oncology (Lung cancer, Head and neck cancer, Esophageal cancer)


schedule of week
01 THU
AM available
PM available

Medical School

Hanyang University College of Medicine

Specialty Training

Specialty Training
Fellowship   Asan Medical Center
Residency   Hanyang University Hospital
Internship   Hanyang University Hospital

Other Education

  • Master: Hanyang University Graduate School
    Ph.D: Hanyang University Graduate School
    Postdoctoral fellowship: Memorial Sloan Kettering Cancer Center, USA

Participation in Academic Societies
and Research

  • Member, Korean Medical Association
    Member, Korean Association of Internal Medicine
    Member, Korean Association of Oncology
    Member, Korean Association for Cancer Research
    Member, American Society of Oncology
    Member, International Association Society of Lung Cancer
    Member, European Society of Medical Oncology
    Member, Korean Association of Clinical Oncology
    Member, Korean Association Society of Lung Cancer
    Member, Korean Head and Neck Cancer Society


J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Yang JC11, Ahn MJ1, Kim DW1, Ramalingam SS1, Sequist LV1, Su WC1, Kim SW1, Kim JH1, Planchard D1, Felip E1, Blackhall F1, Haggstrom D1, Yoh K1, Novello S1, Gold K1, Hirashima T1, Lin CC1, Mann H1, Cantarini M1, Ghiorghiu S1, Janne PA1.

Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8.

EGFR TKI combination with immunotherapy in non-small cell lung cancer

Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.

Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Hui R11, Garon EB2, Goldman JW2, Leighl NB3, Hellmann MD4, Patnaik A5, Gandhi L6, Eder JP7, Ahn MJ8, Horn L9, Felip E10, Carcereny E11, Rangwala R12, Lubiniecki GM12, Zhang J12, Emancipator K12, Roach C13, Rizvi NA14.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Drilon A11, Siena S2,3, Ou SI4, Patel M5, Ahn MJ6, Lee J6, Bauer TM7, Farago AF8, Wheler JJ9, Liu SV10, Doebele R11, Giannetta L2, Cerea G2, Marrapese G2, Schirru M2, Amatu A2, Bencardino K2, Palmeri L2, Sartore-Bianchi A2, Vanzulli A2,3, Cresta S12, Damian S12, Duca M12, Ardini E13, Li G14, Christiansen J14, Kowalski K14, Johnson AD14, Patel R14, Luo D14, Chow-Maneval E14, Hornby Z14, Multani PS14, Shaw AT8, De Braud FG3,12.

Support Care Cancer. 2017 Mar;25(3):801-809. doi: 10.1007/s00520-016-3463-0. Epub 2016 Nov 8.

Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types

Kim JE11, Jang JS2, Kim JW3, Sung YL4, Cho CH5, Lee MA6, Kim DJ7, Ahn MJ8, Lee KY9, Sym SJ10, Lim MC11, Jung H12, Cho EK12, Min KW12.


Patients' Rights and Responsibilities

Patients' Rights

1. Right to receive medical care

Patients have the right to receive proper medical and nursing services for their Health Protection and Promotion and they will not be discriminated for gender, age, religion, status, nationality, language, race, or physical/mental/financial circumstances nor be violated of their health. Medical team may not deny medical care without justifiable reason.

2. Right to be informed & autonomous decision

Patients have the right to receive be well-informed and to inquire in detail about the treating physician’s specialty, status of their disease, purpose of the treatment, treatment plan, method, expected results and side effects of the treatment, discharge plan, medical cost, whether or not they are a subject to medical research, organ transplant/donation and etc, and to decide whether to give consent. Patients may stop or deny specific treatment or planned medical care within the ethical guideline and may decide on an alternative treatment.

3. Right to have confidentiality

Patients will not be violated of their rights to confidentiality regarding their physical/health status and privacy. Medical team and facility may not reveal or announce patient’s confidential information, including personal information, unless patient has gives consent or specified in the law, such as criminal investigation.

4. Right to request for consultation and mediation

Patients may request for consultation and mediation from an internal or external agency (Korea Consumer Agency, Korea Medical Dispute Mediation and Arbitration Agency) in the event of any medical dispute.

5. Right to be respected of values or beliefs

Patients will not be discriminated for their culture, religious values or beliefs, and their rights will not be violated.

6. Right to be physically protected and to have stability of mind and bod

Patients have the right to be protected from possible danger in the hospital and to have the stability of mind and body.


1. Responsible to trust and respect the medical team

Patients must accurately inform the medical team of their health condition, trust and respect the medical team’s treatment plan. Patients may be responsible for consequences which results from not following the instruction.

2. Responsible to not use dishonest method for medical treatment

Patients must reveal their identity before receiving any medical care and must not use false or dishonest method, such as receiving medical case under disguised ownership.

3. Responsible to abide by all hospital regulations

Patients must abide by all hospital regulations, respect hospital staff and other patients, and earnestly fulfill the financial obligation to the hospital.